FRESENIUS SE & CO. KGAA #FutureFresenius
Company Presentation
June 2024
Safe Harbor Statement
This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.
Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.
Company Presentation, June 2024 © Fresenius SE & Co. KGaA Investor Relations | 2 |
04
05
01
Company overview
This is Fresenius
OUR MISSION
We save and improve human lives with affordable, accessible and innovative healthcare products and highest quality in clinical care
OUR VISION
We are the trusted, market-leading healthcare company that unites cutting-edge technology and human care to shape next-level therapies
Company Presentation, June 2024 © Fresenius SE & Co. KGaA Investor Relations | 3 |
Healthcare:
Strong needs underpinning secular sector growth
Ageing global population
+40% to 1.4B people >60 years worldwide by 20301
Increasing healthcare spend
Health expenditures rise to >10% of global GDP by 20302
Higher prevalence of chronic diseases
84% of 67M deaths globally in 2030 due to chronic diseases3
Demand for health workforce
10M gap of health and care workers globally by 20304
1 UN Ageing & Health (2021) | 2 OECD Health at a Glance (2019) | 3 Global Burden of Disease, Institute for Health Metrics and Evaluation (2022) | 4 WHO Health Workforce (2023)
4
Focus on Fresenius Kabi and Fresenius Helios
Fresenius Kabi
Fresenius Helios
Pharma | Biopharma | Nutrition | MedTech |
(Bio)Pharma platform
MedTech platform
Care provision platform
Company Presentation, June 2024 © Fresenius SE & Co. KGaA Investor Relations | 7 |
Fresenius Kabi
Strong relevance and scale across our 4 business units
Pharma | Nutrition | MedTech | Biopharma |
Overview
Key facts
Segment share
Revenue 2023
Hospital-sold generic IV | Enteral and Parenteral | Stationary drug delivery | AIID & oncology biologic | |||
Drugs and Fluids | Nutrition products | and therapy devices | drugs (biosimilars) | |||
#1 global IV Drugs | #1 global | #1 global provider | > 100% growth | |||
Parenteral Nutrition | for blood collection | in biopharma '21-'22 | ||||
#3 global IV Fluids | #2 Enteral Nutrition | #2 Infusion Systems | 10+ assets in the | |||
Europe and China | Europe and LATAM | pipeline | ||||
IV Drugs | Parenteral | TCT | Biosimilars | ||||
and CDMO | |||||||
IV Fluids | Enteral1 | INS2 | |||||
€3.8B | €2.3B | €1.5B | €0.4B |
1 Including Ketoanalogues 2 Infusion & Nutrition Systems
Source: IQVIA, Fresenius Kabi internal analysis; market data refers to Fresenius Kabi's addressable markets
Company Presentation, June 2024 © Fresenius SE & Co. KGaA Investor Relations | 8 |
Fresenius Helios
We are the leading hospital care provider in Germany and Spain
80+hospitals
Hospital location
GERMANY SPAIN
#1 hospital provider
(~6% market share)
89%
Share of cases with better performance vs. market average
Position
Quality
#1 private hospital provider | 57 | |
(~12% market share1) | hospitals | |
1st | ||
Hospital group globally to receive | ||
JCI2 accreditation at corporate level |
~78,000
~66,000
in network | Workforce | in network3 | ||
~€7B in 2023 | ~€5B in 2023 | |||
(~60% of total) | Revenues | (~40% of total) | COLOMBIA | |
~9% | ~12% | 7 hospitals4 | ||
EBIT margin in 2023 | EBIT | EBIT margin in 2023 | positioned as medical | |
quality leader |
1 Excludes public-privatepartnerships (PPP) and Occupational risk prevention centers (ORP) | 2 Joint Commission International | 3 Including ~50K employees and ~16K mercantile physicians | 4 7 hospitals in Colombia are included in 57 Quirónsalud hospitals; Clínica Medellín has 2 locations, considered as 2 hospitals | Note: Statements alluding to our leading position refer to our market share based on revenues if not stated otherwise | Source: InEK, German Inpatient Quality Indicators (G-IQI),German Federal Statistical Office, Annual reports, Krankenhaus Rating Report
Company Presentation, June 2024 © Fresenius SE & Co. KGaA Investor Relations | 22 |
Fresenius share & shareholder structure
Share price development LTM (%)
Click to view our interactive share price tool
130
120
110
100
90
80 Jun-23Aug-23Oct-23Dec-23Feb-24Apr-24Jun-24
FRE
DAX
STOXX Europe 600 Health Care
Analyst recommendations (%)
Click to view downloadable set of the consensus data
33
Accumulate/Add/buy/Outperform/Overeight
Equal-weight/Hold/Neutral
67
As of May 2, 2024
Shareholder structure by investors type (%)
8 | 4 | Institutional investors | |
Else Kröner-Fresenius-Stiftung
27 | 61 | Retail holdings | |
Not identified | |||
Shareholder structure by region (%)
11 | 4 3 | |||||
Germany | USA | |||||
12 | 42 | |||||
Rest of Europe | United Kingdom | |||||
28 | Not identified | Other regions | ||||
As of Dec 31, 2023 | As of Dec 31, 2023 |
Company Presentation, June 2024 © Fresenius SE & Co. KGaA Investor Relations | 10 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Fresenius SE & Co. KGaA published this content on 18 June 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 June 2024 16:59:06 UTC.
